Overcoming drug resistance in
ovarian cancer is the overarching goal in gynecologic oncology. One way to increase
drug cytotoxicity without increasing the
drug dose is to simultaneously apply multidrug resistance modulator.
Valspodar is the second generation
P-glycoprotein 1 modulator capable of reversing multidrug resistance in different
cancers. In this study, we evaluated the effect of
valspodar and
cisplatin co-treatment on cell viability, cell death and oxidative status in
ovarian cancer cells. Two human
ovarian cancer cell lines SK-OV-3 and MDAH-2774 were treated with
cisplatin,
valspodar, or
cisplatin +
valspodar for 24 or 48 hours. Untreated cells were used as control group. Cell viability was evaluated by MTT assay. Cell death was assessed by TUNEL and comet assay. Lipid peroxidation (
malondialdehyde) and
protein thiol groups were analyzed as oxidative stress markers. The expression of mitochondrial
superoxide dismutase (MnSOD) was assessed by immunocytochemistry.
Valspodar effectively reduced the resistance of SK-OV-3 cells to
cisplatin, as demonstrated by increased oxidative stress, decreased cell viability and increased apoptosis in SK-OV-3 cells co-treated with
valspodar and
cisplatin compared to other groups. However,
valspodar did not significantly affect the resistance of MDAH-2774 cells to
cisplatin. Stronger staining for MnSOD in MDAH-2774 vs. SK-OV-3 cells after co-treatment with
cisplatin and
valspodar may determine the resistance of MDAH-2774 cell line to
cisplatin.